Cabaletta Bio, Inc. (CABA) SEC Filings

T. Rowe Price Investment Management, Inc. reports holding Cabaletta Bio common stock. It reports 18,869,907 shares beneficially owned, representing 11.6% of the common stock. The firm has sole voting power over 18,776,448 shares and sole dispositive power over 18,869,907 shares, with no shared voting or dispositive power.

The shares are of the company’s common stock, identified by CUSIP 12674W109. T. Rowe Price Investment Management, Inc. also states that this reporting "shall not be construed as an admission" that it is the beneficial owner of these securities and that such beneficial ownership is expressly denied.

Bain Capital Life Sciences Opportunities III, L.P. reports beneficial ownership of common stock of Caballeta Bio, Inc.. As of June 30, 2026, it held 7,709,188 shares of common stock, a warrant to purchase up to 7,500,000 shares, and a pre-funded warrant to purchase up to 6,000,000 shares.

Because of a 9.99% Beneficial Ownership Blocker, Bain Capital Life Sciences may be deemed to beneficially own 17,241,445 shares, or 9.99% of Caballeta Bio’s common stock, based on 163,054,796 shares outstanding plus 9,532,257 shares issuable under the warrants within the blocker. Voting and dispositive power over these securities is shared among affiliated Bain Capital Life Sciences entities.

Cabaletta Bio, Inc., a late-stage clinical biotechnology company developing engineered T cell therapies for autoimmune diseases, reported a Q2 2026 net loss of $51.0 million and a six‑month 2026 net loss of $94.5 million, driven mainly by research and development expenses of $81.8 million for the first half. Cash and cash equivalents increased to $225.1 million at June 30, 2026 from $83.0 million at year‑end 2025, primarily due to a May 2026 equity offering of 51.7 million shares at $2.90 per share and additional at‑the‑market sales. Total assets were $256.7 million with liabilities of $46.1 million and stockholders’ equity of $210.6 million. Management expects current cash to fund operations for at least 12 months but has identified conditions that raise substantial doubt about the ability to continue as a going concern without additional capital beyond the current runway. The company is advancing its lead CD19 CAR‑T candidate rese‑cel through multiple RESET Phase 1/2 and registrational cohorts in myositis, systemic sclerosis, lupus, myasthenia gravis and pemphigus vulgaris, supported by Fast Track, Orphan Drug, Rare Pediatric Disease and RMAT designations in several indications.

Cabaletta Bio reported second quarter 2026 results and updated progress for its lead CAR T cell therapy, rese-cel, across multiple autoimmune indications. Net loss was $51.0 million for the quarter, compared with $45.1 million a year earlier, driven mainly by higher research and development spending of $44.4 million versus $37.6 million. General and administrative expenses were $7.6 million, slightly below $8.3 million in the prior-year quarter.

As of June 30, 2026, Cabaletta held $225.1 million in cash, cash equivalents and short-term investments, up from $133.6 million at year-end 2025, and expects this to fund its operating plan into mid-2027. The company is advancing rese-cel through its RESET program, with registrational RESET-Myositis data expected in mid-2027 to support a planned BLA submission in 2H27, and a registrational SSc-associated ILD cohort targeted to start in 4Q26.

Cabaletta highlighted favorable safety data to support outpatient dosing, PC-free dosing strategies in multiple RESET trials, and expanded manufacturing partnerships with ElevateBio, Lonza and Cellares, including a 10-year commercial supply agreement to support large-scale, potentially lower-cost autologous cell therapy production.

Adage Capital Management, L.P. and related parties report a significant ownership position in Cabaletta Bio, Inc. (CABA). The reporting persons collectively beneficially own 14,174,758 shares of Common Stock, including 5,000,000 shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.

This position represents 8.43% of Cabaletta Bio’s Common Stock, based on 163,054,796 shares outstanding as of May 7, 2026, and assuming exercise of the reported warrants. The reporting persons have shared voting and dispositive power over all 14,174,758 shares and no sole voting or dispositive power. Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross file jointly as reporting persons, with the securities directly held by Adage Capital Partners, L.P.

Norges Bank, the central bank of Norway, reported a significant ownership position in Cabaletta Bio, Inc. common stock on a Schedule 13G. Norges Bank is the beneficial owner of 8,775,653 shares of Cabaletta Bio common stock, representing 5.3820% of the class, as of June 30, 2026. It holds 8,663,310 shares with sole voting power and none with shared voting power. Regarding dispositive power, Norges Bank has sole power over 4,112,401 shares and shared power over 4,663,252 shares. Certain shares are invested on behalf of the Government of Norway, and Norges Bank files in its capacity as an investment adviser under a foreign regulatory regime it states is substantially comparable to that applicable to equivalent U.S. institutions.

Vanguard Capital Management reports a passive ownership stake in Cabaletta Bio Inc common stock on a Schedule 13G. Vanguard and certain listed affiliates beneficially own 8,295,783 shares, representing 5.08% of the outstanding common stock.

Vanguard has sole voting power over 1,068,765 shares and sole dispositive power over all 8,295,783 shares, with no shared voting or dispositive power. The holdings include securities held by various Vanguard funds and managed accounts for which Vanguard entities exercise voting and/or dispositive authority.

BlackRock, Inc. reported beneficial ownership of common stock of Cabaletta Bio, Inc. as of June 30, 2026. BlackRock and its reporting business units beneficially owned 9,613,912 Cabaletta Bio common shares, representing 5.9% of the outstanding class.

BlackRock reported sole voting power over 9,514,478 shares and sole dispositive power over 9,613,912 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or proceeds, but no single client holds more than five percent of Cabaletta Bio’s total outstanding common shares.

Cabaletta Bio, Inc. is reported as having a significant shareholder group led by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. These reporting persons collectively report beneficial ownership of 2,068,491 shares of Cabaletta Bio common stock, representing 1.3% of the class.

The filing states that the reporting persons have no sole voting or dispositive power over these shares, but hold shared voting and shared dispositive power over 2,068,491 shares. The securities are held through entities over which Millennium Management LLC and related managers exercise voting control and investment discretion, and the reporting persons state that this disclosure should not be construed as an admission of beneficial ownership. They also indicate that they now hold 5 percent or less of Cabaletta Bio’s common stock.